

Press Release

Stockholm, Sweden, April 30, 2024

Change in number of shares and votes in Mendus AB (publ)

As previously announced, Mendus AB (publ) ("Mendus") carried out a capital raise of units in July 2023 wherein the exercise period for the warrants issued in the capital raise was during April. In total, 144,043,202 warrants were exercised for subscription of 144,043,202 shares in Mendus.

As a result thereof, the number of shares and votes in Mendus has changed. The issue of shares subscribed for by way of exercising warrants has resulted in an increase in the number of shares from 863,148,371 shares to 1,007,191,573 shares.

As of April 30, 2024, the last trading day of the month, there was a total of 1,007,191,573 shares and votes in Mendus.

This information is such information that Mendus AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act (Sw. lagen om handel med finansiella instrument). The information was submitted for publication through the agency of the contact persons set out below on 30 April 2024, at 08:00 am CEST.

For more information, please contact:

Erik Manting
Chief Executive Officer
E-mail: ir@mendus.com

About Mendus AB (publ)

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. <https://www.mendus.com/>